




10/051,243

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 [@1], [@2], [@3]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 15:03:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1408 TO ITERATE

71.0% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 25909 TO 30411  
PROJECTED ANSWERS: 4 TO 254

L2 4 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:03:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 30238 TO ITERATE

100.0% PROCESSED 30238 ITERATIONS  
SEARCH TIME: 00.00.01

95 ANSWERS

L3 95 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10051243h.str

L4 STRUCTURE UPLOADED

=> s l4 sam

SAMPLE SEARCH INITIATED 15:04:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1408 TO ITERATE

71.0% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 25909 TO 30411  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 full


FULL SEARCH INITIATED 15:05:02 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 30238 TO ITERATE

100.0% PROCESSED 30238 ITERATIONS 12 ANSWERS  
SEARCH TIME: 00.00.01

L6 12 SEA SSS FUL L4

=> d l6

L6 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 484040-87-1 REGISTRY  
CN 1,2-Naphthalenedione, 2-oxime, lithium salt (9CI) (CA INDEX NAME)  
MF C10 H7 N O2 . Li  
SR Chemical Library  
CRN (6373-60-0)



● Li

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
313.87	314.08

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 21 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2004 VOL 141 ISS 26

FILE LAST UPDATED: 20 Dec 2004 (20041220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:02:24 ON 21 DEC 2004)

FILE 'REGISTRY' ENTERED AT 15:02:35 ON 21 DEC 2004

L1 STRUCTURE UPLOADED  
L2 4 S L1 SAM  
L3 95 S L1 FULL  
L4 STRUCTURE UPLOADED  
L5 0 S L4 SAM  
L6 12 S L4 FULL

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 21 DEC 2004

=> s l6

L7 60 L6

=> s l7 and glutamate

93463 GLUTAMATE

1071 GLUTAMATES

93843 GLUTAMATE

(GLUTAMATE OR GLUTAMATES)

L8 2 L7 AND GLUTAMATE

=> d fbib abs hitstr 1-2 l8

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:63831 CAPLUS

DN 134:125960

TI Use of  $\beta$ -naphthoquinone derivatives for making medicines having an inhibiting effect on the release of **glutamate** by the brain

IN Israel, Maurice; Molgo, Jordi; Bloy, Christian; Mattei, Cesar

PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005404	A1	20010125	WO 2000-FR2120	20000721
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2796552	A1	20010126	FR 1999-9469	A 19990721
	EP 1196176	A1	20020417	FR 1999-9469	19990721
	EP 1196176	B1	20040204	EP 2000-958596	20000721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				FR 1999-9469	A 19990721
				WO 2000-FR2120	W 20000721
JP	2003504405	T2	20030204	JP 2001-510459	20000721
				FR 1999-9469	A 19990721
				WO 2000-FR2120	W 20000721
AT	268599	E	20040615	AT 2000-958596	20000721
				FR 1999-9469	A 19990721
				WO 2000-FR2120	W 20000721

PT 1196176

T 20040831

PT 2000-958596

20000721

ES 2215716

T3 20041016

FR 1999-9469

A 19990721

US 2002115617

A1 20020822

ES 2000-958596

20000721

FR 1999-9469

A 19990721

US 2002-51243

20020122


FR 1999-9469

A 19990721


WO 2000-FR2120

A2 20000721

GI



I



II

AB  $\beta$ -Naphthoquinone derivs. are provided for making medicines with an inhibiting effect on the release of **glutamate** by the brain, the derivs. corresponding to I (R = NHCONH<sub>2</sub>, NHCOCH<sub>3</sub>, OH) and glucuronide derivs. II and their pharmaceutically acceptable acid addition salts. The invention is applicable to neurol. diseases.


IT 6373-60-0 15687-37-3 51055-26-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

( $\beta$ -naphthoquinone derivs. for inhibiting release of **glutamate** in brain)


RN 6373-60-0 CAPLUS

CN 1,2-Naphthalenedione, 2-oxime (9CI) (CA INDEX NAME)



RN 15687-37-3 CAPLUS


CN Hydrazinecarboxamide, 2-(1-oxo-2(1H)-naphthalenylydene)- (9CI) (CA INDEX NAME)



RN 51055-26-6 CAPLUS

CN Acetic acid, (1-oxo-2(1H)-naphthalenylydene)hydrazide (9CI) (CA INDEX

NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:520285 CAPLUS

DN 131:346372

TI Naftazone reduces **glutamate** cerebrospinal fluid levels in rats  
and **glutamate** release from mouse cerebellum synaptosomes

AU Mattei, C.; Molgo, J.; Joseph, X.; Israe, M.; Bloy, C.

CS Institute of Medical Sciences, Department of Biomedical Sciences,  
University of Aberdeen, Aberdeen, UK

SO Neuroscience Letters (1999), 271(3), 183-186  
CODEN: NELED5; ISSN: 0304-3940

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

AB It is well known that an excessive release of **glutamate** in the  
mammalian brain plays a major role in several neurol. diseases. Naftazone  
(Etioven®) is a currently used vasoprotectant drug that is metabolized  
in humans by reduction and glucuronidation. In the present study naftazone  
was found to decrease **glutamate** levels in the cerebrospinal  
fluid (CSF) of rats treated for 15 days, as determined by a chemiluminescent  
**glutamate** assay reaction. Naftazone and its glucuronide derivative  
also reduced resp. spontaneous and high K+-evoked **glutamate**  
release from mouse cerebellum synaptosomes. It is likely that naftazone  
and its glucuronide metabolite contribute in vivo to decrease  
**glutamate** levels in the CSF through their inhibitory actions on  
**glutamate** release.


IT 15687-37-3, Naftazone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)

(naftazone reduces **glutamate** cerebrospinal fluid levels in  
rats and **glutamate** release from mouse cerebellum  
synaptosomes)

RN 15687-37-3 CAPLUS

CN Hydrazinecarboxamide, 2-(1-oxo-2(1H)-naphthalenyldene)- (9CI) (CA INDEX  
NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Uploading C:\Program Files\Stnexp\Queries\10051243s.str

L9 STRUCTURE UPLOADED

=> s l9 full

FULL SEARCH INITIATED 15:09:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L10 3 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

156.68	483.42
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-1.40
------	-------

FILE 'CAPLUS' ENTERED AT 15:10:01 ON 21 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2004 VOL 141 ISS 26

FILE LAST UPDATED: 20 Dec 2004 (20041220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10

L11 2 L10

=> s l11 and glutamate

93463 GLUTAMATE

1071 GLUTAMATES

93843 GLUTAMATE

(GLUTAMATE OR GLUTAMATES)

L12 2 L11 AND GLUTAMATE

=> d fbib abs hitstr 1-2 l12

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:63831 CAPLUS

DN 134:125960

TI Use of  $\beta$ -naphthoquinone derivatives for making medicines having an inhibiting effect on the release of glutamate by the brain

IN Israel, Maurice; Molgo, Jordi; Bloy, Christian; Mattei, Cesar

PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2


DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005404	A1	20010125	WO 2000-FR2120	20000721
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2796552	A1	20010126	FR 1999-9469	A 19990721
	EP 1196176	A1	20020417	FR 1999-9469	19990721
	EP 1196176	B1	20040204	EP 2000-958596	20000721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				FR 1999-9469	A 19990721
				WO 2000-FR2120	W 20000721
JP 2003504405	T2	20030204	JP 2001-510459		20000721
			FR 1999-9469	A 19990721	
			WO 2000-FR2120	W 20000721	
AT 268599	E	20040615	AT 2000-958596		20000721
			FR 1999-9469	A 19990721	
			WO 2000-FR2120	W 20000721	
PT 1196176	T	20040831	PT 2000-958596		20000721
			FR 1999-9469	A 19990721	
ES 2215716	T3	20041016	ES 2000-958596		20000721
			FR 1999-9469	A 19990721	
US 2002115617	A1	20020822	US 2002-51243		20020122
			FR 1999-9469	A 19990721	
			WO 2000-FR2120	A2 20000721	

GI



AB  $\beta$ -Naphthoquinone derivs. are provided for making medicines with an inhibiting effect on the release of **glutamate** by the brain, the derivs. corresponding to I (R = NHCONH<sub>2</sub>, NHCOCH<sub>3</sub>, OH) and glucuronide derivs. II and their pharmaceutically acceptable acid addition salts. The invention is applicable to neurol. diseases.

IT 250585-74-1 321546-47-8 321546-48-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


( $\beta$ -naphthoquinone derivs. for inhibiting release of **glutamate** in brain)

RN 250585-74-1 CAPLUS

CN  $\beta$ -D-Glucopyranosiduronic acid, 2-[(aminocarbonyl)hydrazono]-1,2-

dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 321546-47-8 CAPLUS

CN  $\beta$ -D-Glucopyranosiduronic acid, 2-(acetylhydrazono)-1,2-dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 321546-48-9 CAPLUS

CN  $\beta$ -D-Glucopyranosiduronic acid, 1,2-dihydro-2-(hydroxyimino)-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.





RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:520285 CAPLUS

DN 131:346372

TI Naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes

AU Mattei, C.; Molgo, J.; Joseph, X.; Israe, M.; Bloy, C.

CS Institute of Medical Sciences, Department of Biomedical Sciences, University of Aberdeen, Aberdeen, UK

SO Neuroscience Letters (1999), 271(3), 183-186

CODEN: NELED5; ISSN: 0304-3940

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

AB It is well known that an excessive release of **glutamate** in the mammalian brain plays a major role in several neurol. diseases. Naftazone (Etioven®) is a currently used vasoprotectant drug that is metabolized in humans by reduction and glucuronidation. In the present study naftazone was found to decrease **glutamate** levels in the cerebrospinal fluid (CSF) of rats treated for 15 days, as determined by a chemiluminescent **glutamate** assay reaction. Naftazone and its glucuronide derivative also reduced resp. spontaneous and high K<sup>+</sup>-evoked **glutamate** release from mouse cerebellum synaptosomes. It is likely that naftazone and its glucuronide metabolite contribute in vivo to decrease **glutamate** levels in the CSF through their inhibitory actions on **glutamate** release.

IT 250585-74-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(naftazone reduces **glutamate** cerebrospinal fluid levels in rats and **glutamate** release from mouse cerebellum synaptosomes)

RN 250585-74-1 CAPLUS

CN β-D-Glucopyranosiduronic acid, 2-[(aminocarbonyl)hydrazono]-1,2-dihydro-1-naphthalenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT